These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 31839676)

  • 1. Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer.
    Hunter FW; Barker HR; Lipert B; Rothé F; Gebhart G; Piccart-Gebhart MJ; Sotiriou C; Jamieson SMF
    Br J Cancer; 2020 Mar; 122(5):603-612. PubMed ID: 31839676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond.
    García-Alonso S; Ocaña A; Pandiella A
    Trends Cancer; 2020 Feb; 6(2):130-146. PubMed ID: 32061303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibody-Drug Conjugate Drug Development in Solid Tumors.
    Pegram MD; Miles D; Tsui CK; Zong Y
    Clin Cancer Res; 2020 Feb; 26(4):775-786. PubMed ID: 31582515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer.
    Barok M; Le Joncour V; Martins A; Isola J; Salmikangas M; Laakkonen P; Joensuu H
    Cancer Lett; 2020 Mar; 473():156-163. PubMed ID: 31904483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of ado-trastuzumab emtansine in current clinical practice.
    Turshudzhyan A
    J Oncol Pharm Pract; 2021 Jan; 27(1):150-155. PubMed ID: 32838683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy.
    Molinelli C; Parisi F; Razeti MG; Arecco L; Cosso M; Fregatti P; Del Mastro L; Poggio F; Lambertini M
    Expert Rev Anticancer Ther; 2021 Mar; 21(3):241-250. PubMed ID: 33245671
    [No Abstract]   [Full Text] [Related]  

  • 7. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
    Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
    Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of T-DM1-resistant breast cancer cells.
    Sauveur J; Conilh L; Beaumel S; Chettab K; Jordheim LP; Matera EL; Dumontet C
    Pharmacol Res Perspect; 2020 Aug; 8(4):e00617. PubMed ID: 32583565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer.
    Gedik ME; Saatci O; Oberholtzer N; Uner M; Akbulut Caliskan O; Cetin M; Aras M; Ibis K; Caliskan B; Banoglu E; Wiemann S; Üner A; Aksoy S; Mehrotra S; Sahin O
    Cancer Res; 2024 May; 84(9):1475-1490. PubMed ID: 38319231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation.
    Yamashita-Kashima Y; Shu S; Osada M; Fujimura T; Yoshiura S; Harada N; Yoshimura Y
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):641-654. PubMed ID: 32997196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralization of BCL-2/X
    Zoeller JJ; Vagodny A; Taneja K; Tan BY; O'Brien N; Slamon DJ; Sampath D; Leverson JD; Bronson RT; Dillon DA; Brugge JS
    Mol Cancer Ther; 2019 Jun; 18(6):1115-1126. PubMed ID: 30962322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evolving role of trastuzumab emtansine (T-DM1) in HER2-positive breast cancer with brain metastases.
    Dong R; Ji J; Liu H; He X
    Crit Rev Oncol Hematol; 2019 Nov; 143():20-26. PubMed ID: 31449983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer.
    Wang L; Wang Q; Gao M; Fu L; Li Y; Quan H; Lou L
    Cancer Sci; 2018 Oct; 109(10):3305-3315. PubMed ID: 30076657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer.
    Delgado J; Vleminckx C; Sarac S; Sosa A; Bergh J; Giuliani R; Enzmann H; Pignatti F
    ESMO Open; 2021 Apr; 6(2):100074. PubMed ID: 33647599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development.
    Fujihara M; Shien T; Shien K; Suzawa K; Takeda T; Zhu Y; Mamori T; Otani Y; Yoshioka R; Uno M; Suzuki Y; Abe Y; Hatono M; Tsukioki T; Takahashi Y; Kochi M; Iwamoto T; Taira N; Doihara H; Toyooka S
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q.
    Jhaveri KL; Wang XV; Makker V; Luoh SW; Mitchell EP; Zwiebel JA; Sharon E; Gray RJ; Li S; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
    Ann Oncol; 2019 Nov; 30(11):1821-1830. PubMed ID: 31504139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer.
    Lyseng-Williamson KA
    Drugs; 2020 Nov; 80(16):1723-1730. PubMed ID: 32996066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab emtansine: mechanisms of action and drug resistance.
    Barok M; Joensuu H; Isola J
    Breast Cancer Res; 2014 Mar; 16(2):209. PubMed ID: 24887180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate.
    Yamashita-Kashima Y; Yoshimura Y; Fujimura T; Shu S; Yanagisawa M; Yorozu K; Furugaki K; Higuchi R; Shoda J; Harada N
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):659-671. PubMed ID: 30659304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.
    Krop I; Winer EP
    Clin Cancer Res; 2014 Jan; 20(1):15-20. PubMed ID: 24135146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.